This ADC consists of an anti-HER2 mAb linked to monomethyl auristatin E (MMAE) and has shown a favorable safety profile and promising anti-tumor activity in late-stage HER2-positive solid tumors, including GC. The gene discussed is ERBB2; the disease is neoplasm.